Šizofrenija sergančių artimųjų santykių pokyčiai ir stigmatizacijos patirtis pirminiame socialiniame tinkle

The goal of this article is to analyze the challenges that arise from stigma and that relatives of people with Schizophrenia face in their relationships in primary social network. Schizophrenia does not only change everyday life and relationships of the ill but also of their relatives. This topic is not researched in Lithuania. Meanwhile in the international context, the biggest attention is paid to the subjective and objective burden that relatives of the people with Schizophrenia face, leaving aside the changes and dynamics in their relationships. Therefore, in this article the influence of the stigmatization on the relationships in the closest environment of patient is discussed. In order to achieve this goal, qualitative research has been completed and 15 half-structured interviews with the people who have relatives, who suffer from Schizophrenia, were carried out. The relation to the person with Schizophrenia varied according to the individual cases – some of them were spouses, some where children, parents, siblings or further relatives. The results of the research reveal that Schizophrenia causes complex emotional experiences of patient’s family members, and gives an effect on relationships within the family, as well as on relationships of the ill and his family members with further relatives, friends, neighbors and colleagues.KEY WORDS: schizophrenia, relatives of persons with schizophrenia, stigma, relationships

Results of the COVID-19 mental health international for the general population (COMET-G) study.

INTRODUCTION: There are few published empirical data on the effects of COVID-19 on mental health, and until now, there is no large international study. MATERIAL AND METHODS: During the COVID-19 pandemic, an online questionnaire gathered data from 55,589 participants from 40 countries (64.85% females aged 35.80 ± 13.61; 34.05% males aged 34.90±13.29 and 1.10% other aged 31.64±13.15). Distress and probable depression were identified with the use of a previously developed cut-off and algorithm respectively. STATISTICAL ANALYSIS: Descriptive statistics were calculated. Chi-square tests, multiple forward stepwise linear regression analyses and Factorial Analysis of Variance (ANOVA) tested relations among variables. RESULTS: Probable depression was detected in 17.80% and distress in 16.71%. A significant percentage reported a deterioration in mental state, family dynamics and everyday lifestyle. Persons with a history of mental disorders had higher rates of current depression (31.82% vs. 13.07%). At least half of participants were accepting (at least to a moderate degree) a non-bizarre conspiracy. The highest Relative Risk (RR) to develop depression was associated with history of Bipolar disorder and self-harm/attempts (RR = 5.88). Suicidality was not increased in persons without a history of any mental disorder. Based on these results a model was developed. CONCLUSIONS: The final model revealed multiple vulnerabilities and an interplay leading from simple anxiety to probable depression and suicidality through distress. This could be of practical utility since many of these factors are modifiable. Future research and interventions should specifically focus on them

Staging of Schizophrenia with the Use of PANSS: An International Multi-Center Study

Introduction: A specific clinically relevant staging model for schizophrenia has not yet been developed. The aim of the current study was to evaluate the factor structure of the PANSS and develop such a staging method.Methods: Twenty-nine centers from 25 countries contributed 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Analysis of covariance, Exploratory Factor Analysis, Discriminant Function Analysis, and inspection of resultant plots were performed.Results: Exploratory Factor Analysis returned 5 factors explaining 59% of the variance (positive, negative, excitement/hostility, depression/anxiety, and neurocognition). The staging model included 4 main stages with substages that were predominantly characterized by a single domain of symptoms (stage 1: positive; stages 2a and 2b: excitement/hostility; stage 3a and 3b: depression/anxiety; stage 4a and 4b: neurocognition). There were no differences between sexes. The Discriminant Function Analysis developed an algorithm that correctly classified >85% of patients.Discussion: This study elaborates a 5-factor solution and a clinical staging method for patients with schizophrenia. It is the largest study to address these issues among patients who are more likely to remain affiliated with mental health services for prolonged periods of time.<br /

Changes in the relationships and experiences of stigmatization in the primary social network of relatives of persons with schizophrenia

The goal of this article is to analyze the challenges that arise from stigma and that relatives of people with Schizophrenia face in their relationships in primary social network. Schizophrenia does not only change everyday life and relationships of the ill but also of their relatives. This topic is not researched in Lithuania. Meanwhile in the international context, the biggest attention is paid to the subjective and objective burden that relatives of the people with Schizophrenia face, leaving aside the changes and dynamics in their relationships. Therefore, in this article the influence of the stigmatization on the relationships in the closest environment of patient is discussed. In order to achieve this goal, qualitative research has been completed and 15 half-structured interviews with the people who have relatives, who suffer from Schizophrenia, were carried out. The relation to the person with Schizophrenia varied according to the individual cases – some of them were spouses, some where children, parents, siblings or further relatives. The results of the research reveal that Schizophrenia causes complex emotional experiences of patient’s family members, and gives an effect on relationships within the family, as well as on relationships of the ill and his family members with further relatives, friends, neighbors and colleagues

Ruffe (Gymnocephalus cernuus L.) growth and diet in Lake Dusia (southern Lithuania)

Fisheries Institute in Olsztyn, Poland Citation: Pilinkovskij A., Kesminas V., Bukelskis E., ivas L. 2014 -Ruffe (Gymnocephalus cernuus L.) growth and diet in Lake Dusia (southern Lithuania) -Arch. Pol. Abstract. The ruffe, Gymnocephalus cernuus (L.), is considered to be a food competitor with many commercially valuable fishes such as bream, Abramis brama (L.), roach, Rutilus rutilus (L.), pikeperch, Sander lucioperca (L.), and perch, Perca fluviatilis L. This paper presents the results of an investigation into the fish community structure of Lake Dusia and the population parameters (morphometry, age, growth, diet) of ruffe as one of the prevailing fish species in the lake. The fish community of Lake Dusia was dominated by ruffe, perch, and roach. The ruffe population constituted 64.1% of the fish community of the lake in relative abundance and 36.8% in biomass. An analysis of the ruffe diet revealed that Gammaridae and Chironomidae were the principal components in all age-classes. The ruffe population was comprised mainly of individuals 3+ and 4+ years of age. The mean total length (TL) of ruffe was 13.39 ± 1.79 cm (minimum-maximum: 6.12-19.93 cm). The growth in length calculated using the von Bertalanffy equation was L t = 21.3 [1-e -0.161(t-0.335) ]. Ruffe growth rates were found to slow as the fish aged. Ruffe growth variations were linked to population density, fish community structure in the water body, abundance of invertebrates (zooplankton and zoobenthos), and type of water body

Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia : an international multicenter study

Background The aim of the current study was to explore the effect of gender, age at onset, and duration on the long-term course of schizophrenia. Methods Twenty-nine centers from 25 countries representing all continents participated in the study that included 2358 patients aged 37.21 +/- 11.87 years with a DSM-IV or DSM-5 diagnosis of schizophrenia; the Positive and Negative Syndrome Scale as well as relevant clinicodemographic data were gathered. Analysis of variance and analysis of covariance were used, and the methodology corrected for the presence of potentially confounding effects. Results There was a 3-year later age at onset for females (P &lt; .001) and lower rates of negative symptoms (P &lt; .01) and higher depression/anxiety measures (P &lt; .05) at some stages. The age at onset manifested a distribution with a single peak for both genders with a tendency of patients with younger onset having slower advancement through illness stages (P = .001). No significant effects were found concerning duration of illness. Discussion Our results confirmed a later onset and a possibly more benign course and outcome in females. Age at onset manifested a single peak in both genders, and surprisingly, earlier onset was related to a slower progression of the illness. No effect of duration has been detected. These results are partially in accord with the literature, but they also differ as a consequence of the different starting point of our methodology (a novel staging model), which in our opinion precluded the impact of confounding effects. Future research should focus on the therapeutic policy and implications of these results in more representative samples

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

INTRODUCTION: A specific clinically relevant staging model for schizophrenia has not yet been developed. The aim of the current study was to evaluate the factor structure of the PANSS and develop such a staging method. METHODS: Twenty-nine centers from 25 countries contributed 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Analysis of covariance, Exploratory Factor Analysis, Discriminant Function Analysis, and inspection of resultant plots were performed. RESULTS: Exploratory Factor Analysis returned 5 factors explaining 59% of the variance (positive, negative, excitement/hostility, depression/anxiety, and neurocognition). The staging model included 4 main stages with substages that were predominantly characterized by a single domain of symptoms (stage 1: positive; stages 2a and 2b: excitement/hostility; stage 3a and 3b: depression/anxiety; stage 4a and 4b: neurocognition). There were no differences between sexes. The Discriminant Function Analysis developed an algorithm that correctly classified >85% of patients. DISCUSSION: This study elaborates a 5-factor solution and a clinical staging method for patients with schizophrenia. It is the largest study to address these issues among patients who are more likely to remain affiliated with mental health services for prolonged periods of time.status: publishe

Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study.

BACKGROUND.: The aim of the current study was to explore the changing interrelationships among clinical variables through the stages of schizophrenia in order to assemble a comprehensive and meaningful disease model. METHODS.: Twenty-nine centers from 25 countries participated and included 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Multiple linear regression analysis and visual inspection of plots were performed. RESULTS.: The results suggest that with progression stages, there are changing correlations among Positive and Negative Syndrome Scale factors at each stage and each factor correlates with all the others in that particular stage, in which this factor is dominant. This internal structure further supports the validity of an already proposed four stages model, with positive symptoms dominating the first stage, excitement/hostility the second, depression the third, and neurocognitive decline the last stage. CONCLUSIONS.: The current study investigated the mental organization and functioning in patients with schizophrenia in relation to different stages of illness progression. It revealed two distinct "cores" of schizophrenia, the "Positive" and the "Negative," while neurocognitive decline escalates during the later stages. Future research should focus on the therapeutic implications of such a model. Stopping the progress of the illness could demand to stop the succession of stages. This could be achieved not only by both halting the triggering effect of positive and negative symptoms, but also by stopping the sensitization effect on the neural pathways responsible for the development of hostility, excitement, anxiety, and depression as well as the deleterious effect on neural networks responsible for neurocognition.status: Published onlin

Staging of Schizophrenia With the Use of PANSS : An International Multi-Center Study

Introduction A specific clinically relevant staging model for schizophrenia has not yet been developed. The aim of the current study was to evaluate the factor structure of the PANSS and develop such a staging method. Methods Twenty-nine centers from 25 countries contributed 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Analysis of covariance, Exploratory Factor Analysis, Discriminant Function Analysis, and inspection of resultant plots were performed. Results Exploratory Factor Analysis returned 5 factors explaining 59% of the variance (positive, negative, excitement/hostility, depression/anxiety, and neurocognition). The staging model included 4 main stages with substages that were predominantly characterized by a single domain of symptoms (stage 1: positive; stages 2a and 2b: excitement/hostility; stage 3a and 3b: depression/anxiety; stage 4a and 4b: neurocognition). There were no differences between sexes. The Discriminant Function Analysis developed an algorithm that correctly classified &gt;85% of patients. Discussion This study elaborates a 5-factor solution and a clinical staging method for patients with schizophrenia. It is the largest study to address these issues among patients who are more likely to remain affiliated with mental health services for prolonged periods of time.Funding Agencies|NHMRC Senior Principal Research FellowshipNational Health and Medical Research Council of Australia [APP1059660, APP1156072]</p